Patent ID: 6194436
Filing Date: 2001-02-27
Classification: A61K

Abstract:
A method of treating small cell lung carcinoma, extra pulmonary small cell carcinoma or a neuroendocrine tumor in a mammal in need of such treatment, comprising administering to said mammal a therapeutically effective amount of an NK-1 receptor antagonist selected from the group consisting of2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]methylamide ;N-(4,5-dimethylthiazol-2-yl)-N-[4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-yl -aminomethyl)phenyl]methanesulfonamide;{5-[(4,5-dimethylthiazol-2-yl)methylamino]2-methoxybenzyl }-((2S,3S)-2-phenylpiperidin-3-yl)amine;{5-(4,5-dimethylthiazol-2-ylamino)-2-methoxybenzyl}-((2S,3S)-2-phenylpiperi din-3-ylamine;4,5-dimethylthiazole-2-sulfonic acid methyl-[3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)-4-trifluoromethoxyph enyl]amide;2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]methylam ide;2,4-dimethylthiazole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]isopropy lamide;2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]isopropylam ide;2,4-dimethylthiazole-5-sulfonic acid [4-methoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]isobutylami de;2,4-dimethylthiaxole-5-sulfonic acid [4-isopropoxy-3-((2S,3S)-2-phenylpiperidin-3-ylaminomethyl)phenyl]isobutyl amide;and the pharmaceutically acceptable salts of the foregoing compounds.